Search
Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB14604ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza B virus B/Massachusetts/2/2012 BX-51B antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB14605ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Texas/50/2012 (H3N2) live (attenuated) antigen
go.drugbank.com/drugs/DB14606ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza B virus B/Wisconsin/1/2010) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB14609ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB14614ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Wisconsin/588/2019 (H1N1) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB16706ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Tasmania/503/2020 IVR-221 (H3N2) antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB16721ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Kansas/14/2017 X-327 (H3N2) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB15501ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Idaho/07/2018 (H1N1) antigen (MDCK cell derived, propiolactone inactivated
go.drugbank.com/drugs/DB15505ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Influenza A virus A/Switzerland/3330/2017 (H1N1) live (attenuated) antigen
go.drugbank.com/drugs/DB15513ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen